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Objective: To forecast the burden of symptomatic knee osteoarthritis (OA) in the elderly US population
over a 10-year horizon.
Design: Using a computer simulation model of the natural history and management of knee OA combined
with population-based data from the 2008 US Census we projected the 10-year burden of knee OA
among persons 60e64 years of age. Knee OA incidence and progression rates were derived from national
cohorts and calibrated to published literature.
Results: Using national data we estimated that 13% of 14,338,292 adults 60e64 years old have prevalent
symptomatic, radiographic knee OA. Among persons surviving the next decade, 20% will have symp-
tomatic advanced (KellgreneLawrence [KeL] grade 3) or end-stage (KeL 4) knee OA. Prevalence of
advanced knee OA will range from 10% among non-obese to 35% among obese persons. Our estimates
show that a more sensitive imaging tool, such as magnetic resonance imaging (MRI), may increase the
number of OA cases diagnosed by up to 94% assuming that 50% of all ‘pre-radiographic knee OA’ (KeL 1)
has some evidence of cartilage degeneration seen on MRI.
Conclusions: Projecting new and advanced cases of knee OA among persons aged 60e64 years over the
next decade creates a benchmark that can be used to evaluate population-based beneﬁts of future
disease-modifying OA drugs that are currently undergoing testing at various stages.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Knee osteoarthritis (OA) is a debilitating disorder that primarily
affects older adults. Approximately 12e16% of US adults older than
60 years of age suffer from symptomatic knee OA1,2. A growing
body of evidence suggests that obesity is a salient risk factor for
knee OA incidence andmay play a role in the disease’s symptomatic
progression3e6. Often working in concert with other risk factors,Elena Losina, Orthopedic and
Women’s Hospital, 75 Francis
7-732-5338; Fax: 1-617-525-
s Research Society International. Pobesity exacerbates OA incidence risk through mechanical load
and, likely, through metabolic pathways7,8.
In the US, the obesity epidemic and aging baby-boomer pop-
ulation augur accelerated rates of kneeOA incidence9. This increasing
volume of OA cases may also be accompanied by an increased utili-
zation of pharmaceutical and surgical interventions10e12. In addition,
if more sensitive diagnostic tools such as magnetic resonance
imaging (MRI) are implemented in OA diagnosis, rates of OA diag-
nosis can be expected to rise.
Our objective was to estimate the 10-year cumulative inci-
dence and progression rates of knee OA in a deﬁned population of
persons aged 60e64 years. Long-term estimates for knee OA
burden using current treatments will serve as benchmarks against
which the population-based impact of newly developed disease-
modifying regimens could be evaluated. Projections will inform
clinicians and policy makers in evaluating the capacity of theublished by Elsevier Ltd. All rights reserved.
H.L. Holt et al. / Osteoarthritis and Cartilage 19 (2011) 44e50 45health care system to address the growing epidemic of obesity and
knee OA.
Methods
Analytic overview
We used the Osteoarthritis Policy (OAPol) Model to estimate the
cumulative incidence rates of symptomatic advanced or end-stage
knee OA over a 10-year time horizon in a population of persons aged
60e64 with demographic and obesity proﬁles similar to the general
USpopulation. Cohort characteristicswereobtained fromtheCenters
for Disease Control and Prevention (CDC) 2008 projections of the US
2000 Census, from the Third National Health and Nutrition Exami-
nation Survey (NHANES III), and from the NHANES 2007e200813e16.
Cumulative incidence of symptomatic advanced or end-stage knee
OA was deﬁned as the proportion of the original cohort alive at the
10-year follow-up with symptomatic advanced (KellgreneLawrence
[KeL] 3) or end-stage (KeL 4) knee OA. Cumulative incidence rates
were estimated separately for obese and non-obese persons. We
forecast additional diagnosable cases of knee OA by expanding the
deﬁnition of knee OA to encompass pre-radiographic OA (KeL 1)
usingMRI. To estimate the burden of disability among those affected
by knee OA we applied data from 2005 to 2008 NHANES data on
functional disability, deﬁnedas difﬁculty inwalking and kneeling, for
individuals between 70 and 74 years of age with OA, reﬂecting the
study population 10 years from baseline.
The OAPol Model
The OAPolModel is a state transition, computer simulationmodel
of the natural history of knee OA that runs on an annual cycle. “StateTable I
OAPOL Model input parameters
Parameter
Mean age*
BMIy Mean standard deviation (kg/m2)
Non-obese
Obese
% Female13
Race distributions for the US population by sex13
African American non-Hispanic
Caucasian Hispanic
Caucasian non-Hispanic
Comorbidity Prevalence17 (%)
Diabetes mellitus 7.20e37.28
Coronary heart disease 3.84e27.17
Cancer 1.77e8.68
Chronic obstructive pulmonary disorder 8.83e16.51
Musculoskeletal disorders other than OA 23.96e46.52
Obesity (30 kg/m2 BMI)z User-deﬁned
Knee OA incidence and progression estimates (annual probability, %)
Sex Obesity Age group Incidence16,20,25 (95% CI)
Females Non-obese 60e64 0.18 (0.09, 0.35)
65e74 0.44 (0.23, 0.83)
Obese 60e64 0.42 (0.21, 0.84)
65e74 1.05 (0.56, 1.99)
Males Non-obese 60e64 0.16 (0.08, 0.33)
65e74 0.31 (0.16, 0.59)
Obese 60e64 0.39 (0.19, 0.78)
65e74 0.74 (0.38, 1.42)
* Mean age and standard deviation deﬁned by user for analyses.
y Mean BMIs and standard deviations deﬁned by user for analyses.
z Obesity prevalence determined by the user’s deﬁnition for mean BMI distribution. O
on subject’s age, race/ethnicity and sex.transition” refers to the fact that the model characterizes each
person’s history as a sequence of annual transitions from one health
state to another. Annual transition probabilities used in the OAPol
model, derived from published data or secondary data analyses, are
presented in Table I. Health states are chosen to describe the indi-
vidual’s current health, including the number of comorbidities,
obesity status and knee OA status. They are designed to be predictive
of comorbidities andmortality. Themodel deﬁnes four general health
state categories: knee OA- and obesity-free, knee OA only, obesity
only, knee OA and obesity. Throughout most of their lives, patients
reside in one of these chronic states. Death can occur in any state.
The OAPol Model utilizes the KeL scale to deﬁne OA severity:
KeL 0 (normal radiograph) is deﬁned as ‘no OA,’ KeL 1 (question-
able osteophytes) as ‘pre-radiographic OA,’ KeL 2 (deﬁnite osteo-
phytes) as ‘early OA,’ KeL 3 (<50% narrowing of knee joint space) as
‘advanced OA,’ and KeL 4 (50% narrowing of joint space) as ‘end-
stage OA’. Symptomatic knee OA is deﬁned as the concomitant
presence of radiographic knee OA and knee pain on most days.
The OAPol Model tracks subjects’ life courses until death. Over
their life spans, subjects without knee OA are at risk for developing
OA and subjects with the disease are at risk for progressing to more
advanced stages based on subjects’ current KeL grade and obesity,
as deﬁned by body mass index (BMI).
Knee OA incidence and progression rates in the OAPol Model are
stratiﬁed by obesity and sex. Incidence is further stratiﬁed by age
and progression is further stratiﬁed by KeL grade. At the beginning
of a simulation, subjects are assigned a KeL grade and symptom
status, based on their age and BMI. During each model cycle
(1 year), subjects may develop knee OA if they are currently OA-free
or progress by one KeL grade if they already have OA. For example,
a subject with symptomatic early OA (KeL 2) at baseline surviving
to the following year may be assigned one of two states: (1)Estimate
62.00 0.67
25.00 0.67
32.50 0.67
52.02
Female (%) Male (%)
10.83 9.22
8.40 8.21
80.77 82.56
Annual incidence17 (%) Relative risk of mortality18,19,36
0.29e7.20 1.00
0.16e8.65 1.00e3.56
0.10e3.33 1.00e17.32
0.38e3.07 1.00
1.46e17.42 1.00
0 1.19e2.85
Progression KeL 2e32,5 (95% CI) Progression KeL 3e42,5 (95% CI)
4.00
(2.18, 5.97)
1.95
(0.39, 5.67)
8.95
(4.95, 13.19)
4.27
(0.87, 12.16)
5.58
(3.06, 8.30)
1.29
(0.26, 3.80)
12.26
(6.83, 17.90)
2.94
(0.60, 8.48)
besity progression was derived from NHANES 2007e2008 as a formula dependent
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advanced OA (KeL 3).
Competing risks for mortality are accounted for in the OAPol
Model by incorporating several major comorbidities including
cardiovascular disease, diabetes, chronic obstructive pulmonary
disorders and malignancies. Comorbidity prevalence and incidence
rates, stratiﬁed by age, sex, race/ethnicity and obesity state (non-
obese, obese, and morbidly obese), were derived using NHANES III
data and the US 2000 life tables17,18 (Table I). Subjects that develop
comorbidities may have a greater annual mortality risk. Excess
mortality attributable to speciﬁc comorbidities is estimated from
published literature and CDC national statistics14,18,19. The life
expectancy derived from the OAPol Model approximates the life
expectancy derived from CDC data with a high degree of accuracy,
with differences for a baseline population of 60e64 years of age not
exceeding 0.5 years18.
Cohorts under consideration
We considered several hypothetical cohorts deﬁned by a speciﬁc
combination of three conditions at baseline: symptom status
(asymptomatic vs symptomatic), obesity status (non-obese:
BMI< 30 kg/m2 vs obese: BMI 30 kg/m2) and KeL grade (1e4) for
a population cohort of individuals 60e64 years of age at baseline.We
followed each of these cohorts over a 10-year time span estimating
the number of newly developed or progressed to advanced or end-
stage level knee OA cases among 10-year survivors.
Data sources
Model input parameters and transition probabilities are pre-
sented in Table I.
The size of the US population aged 60e64 years old was obtained
from the US Census Bureau’s 2008 population annual estimates13.
NHANES III and NHANES 2007e2008 data were combined to deter-
mine the demographic characteristics of this population stratiﬁed by
all permutations of obesity, symptom status and degree of radio-
graphic OA severity. The radiographic knee OA data (KeL 0 to KeL 4)
at baseline were derived from NHANES III data, as knee OA-related
data were not available in the NHANES 2007e2008, while radio-
graphs were performed from 1991 to 1994 for all NHANES III
participants aged 60þ15,16. Age/sex/race/obesity stratiﬁed prevalence
rates for comorbidities used in the OAPol model (obesity, diabetes,
coronary heart disease, malignancies, non-OA musculoskeletal
disorders, and chronic obstructive pulmonary disorder)were derived
from NHANES III data17.
We derived annual symptomatic knee OA incidence from pub-
lished data and progression rates using data from the Johnston
CountyOsteoarthritis Project, a prospective population-based study
of knee OA incidence and progression in Caucasians and African-
Americans in North Carolina. The details of this study have been
published elsewhere20,2. The OAPol Model’s knee OA progression
matrix contains ﬂexible components that enable calibration of
progression parameters used in the model to published data or
independent cohorts. To derive base case progression estimates we
calibrated the 5-year cumulative knee OA progression estimates
obtained from the Johnston County Osteoarthritis Project to 5-year
cumulative rates reported in a prospective population-based study
by Cooper et al.5. Transition probabilities of knee OA progression
stratiﬁed by obesity and KeL grade are presented in Table I.
Analysis assumptions
Based on published literature assessing population need for and
willingness to undergo total knee replacement (TKR), we assumedthat approximately 33% of the population with symptomatic end-
stage (KeL 4) knee OAwould elect TKR. This assumption is based on
population-based estimates of willingness to undergo TKR docu-
mented by Hawker and colleagues21. To further substantiate this
assumption, we calibrated the rates of offer and acceptance of TKR
among eligible simulated patients in the model with observed rates
of TKR utilization in the US.
To evaluate the implications of a new OA deﬁnition where some
pre-radiographic knee OA is detectable by more sensitive imaging
techniques, we assumed that 50% of ‘pre-radiographic OA’ (for
which we used KeL 1 as a proxy) would be observable by MRI and
diagnosed as ‘early OA’.
Sensitivity analyses
To examine the robustness of our projections to variability in
model input parameters we conducted several sensitivity analyses.
To account for uncertainty, we conducted sensitivity analyses using
the lower and upper 95% conﬁdence intervals of incidence and
progression rate estimates.
We examined the effect on our projections of increasing or
decreasing the difference in incidence and progression of knee OA
between obese and non-obese individuals by 50%. We also varied
the percent of the population with KeL 4 symptomatic knee OA
receiving TKR from 22% to 44%.
Next, we deﬁned ‘less conservative’ and ‘more conservative’ case
scenarios considering knee OA incidence and progression estimates
obtained from different cohorts. Incidence and progression rates
corresponding to FraminghamOsteoarthritis Study (FOS) data led to
themost conservative projections andwere referred to as the ‘more
conservative’ scenario22. The ‘less conservative case’ (highest rates
of knee OA progression) scenario was based on estimates directly
obtained from the Johnston County Osteoarthritis Project, which
was characterized by a larger proportion of racial and ethnic
minorities, a rural population, and a BMI greater than the national
average2.
The ﬁnal round of sensitivity analyses was focused on varying
the deﬁnition of early OA by varying the proportion of KeL 1
patients diagnosed with pre-radiographic OA from 0% to 100%.
Results
Projecting knee OA burden in an overall population of adults
60e64 years of age
Applying the NHANES-derived obesity distributions to the
Census 2008 population size, we estimated the size of the US
population 60e64 years old (Caucasian or African American race,
Hispanic or non-Hispanic ethnicity) to be 14,338,292 persons13,16,17.
Of these adults, about 43% are obese and 33% have evidence of
radiographic knee OA (KeL 2) (Table II).
We estimated that 80% of obese and 86% of non-obese adults
would survive 10 years beyond the baseline. Of the surviving adults,
20%, or 2,442,582 individuals, will have symptomatic advanced or
end-stage knee OA. These estimates are derived assuming 33% of
adults with symptomatic end-stage knee OA elect TKR, resulting in
disease ‘resolution’21. Ten percent (689,996 adults) of the surviving
non-obese population compared with 35% (1,752,586 adults) of the
surviving obese population will have symptomatic advanced or
end-stage knee OA.
Among obese adults free of radiographic knee OA at the base-
line, the estimated rates of advanced or end-stage knee OA range
from 2% of those alive at year 10 for obese to 0.4% among non-obese
adults. Obese adults with early OA (KeL 2) at baseline have an
estimated 63% 10-year risk of developing symptomatic advanced or
Table II
10-year projected burden of symptomatic advanced and end-stage knee OA in the US population 60e64 years of age at baseline
Baseline KeL state Baseline obesity status Baseline N 10-year results
% Survived
(# of survivors)
% Survived with symptomatic
KeL 3 or 4 knee OA (#)
0, 1 (no evidence of radiographic OA) Non-obese 6,440,155 86% (5,515,796) 0.43% (23,447)
Obese 3,161,947 80% (2,528,756) 2% (48,682)
2 (Early OA) Non-obese 1,361,985 86% (1,166,498) 37% (434,806)
Obese 2,032,076 80% (1,625,146) 63% (1,016,117)
3 (Advanced OA) Non-obese 206,888 86% (177,193) 95% (168,283)
Obese 762,285 80% (609,635) 90% (547,203)
4 (End-stage OA) Non-obese 110,589 86% (94,716) 67% (63,460)
Obese 262,366 80% (209,826) 67% (140,584)
Overall population 14,338,292 83% (11,927,566) 20% (2,442,582)
Non-obese 8,119,617 86% (6,954,204) 10% (689,996)
Obese 6,218,675 80% (4,973,362) 35% (1,752,586)
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population’s risk of 37%.
Projecting disability burden due to symptomatic knee OA
Data from the NHANES 2007e2008 revealed that disability
burden ranges from 46% for obese to 39% for non-obese persons
aged 70e74 with symptomatic knee OA. Applying these data to our
model-based estimates suggested that 8% of the population cohort
of individuals 60e64 years of age surviving 10 years will experience
substantial disability due to symptomatic knee OA. These estimated
rates vary from 4% in non-obese to 16% in obese persons.
Sensitivity analyses
‘More conservative case’ and ‘less conservative case’ scenarios
The ‘more conservative case’ scenario considering progression
rates consistent with the FOS resulted in a 10-year cumulative
incidence of knee OA of 16%, compared to 20% projections based on
the base case. Estimates corresponding to the ‘less conservative
case’ scenario, using Johnston County Osteoarthritis Project%0
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Fig. 1. Percent of the surviving baseline population with symptomatic advanced or end-s
progression rates were calibrated to rates reported by Cooper et al. (light grey)5. In the ‘more
Model incidence and progression rates were calibrated to FOS and Johnston County Osteoa
overall population with symptomatic advanced (KeL 3) or end-stage (KeL 4) knee OA 10 yea
are depicted by error bars. The asymmetry of the error bars reﬂects utilization of TKR.progression rates, resulted in a higher rate of symptomatic
advanced or end-stage knee OA of 23% (Fig. 1).
Projecting 10-year incidence of knee OA with a ‘pre-radiographic
OA’ deﬁnition
At baseline, 6,975,762 individuals aged 60e64were knee OA free.
Of the 5,884,697 survivors 10 years from baseline, 1.2% will develop
OA detectable by traditional radiographic methods. Assuming 50% of
‘pre-radiographic OA’ subjects are diagnosed as ‘early OA’, the
number of OA cases will almost double, reaching 139,844 cases (2.4%
of survivors). When the proportion of KeL 1 patients diagnosed with
‘pre-radiographicOA’ is increased from50% to 100%, the total number
of diagnosed cases at 10 years will increase by a factor of 1.5 to
207,467.
Varying parameters affecting progression
Altering knee OA incidence and progression rates for obese
individuals relative to those of non-obese persons inﬂuenced the
total burden of OA. Decreasing and increasing the incidence and
progression rates of knee OA by 50% of the difference between
obese and non-obese persons resulted in 10-year estimates ofesaCesa etamitsEevitavresnoCsseL
tage knee OA at 10 years in the ‘base case’ scenario, the OAPol Model incidence and
conservative case’ (dark grey) and ‘less conservative case’ (white) scenarios, the OAPol
rthritis Project data, respectively22,2. The height of each bar depicts the percent of the
rs from the baseline. The uncertainty in progression and incidence parameter estimates
H.L. Holt et al. / Osteoarthritis and Cartilage 19 (2011) 44e5048symptomatic advanced or end-stage knee OA rates of 19% and 22%,
respectively (base case was 20%).
Varying the percent of subjects with symptomatic end-stage
knee OA that received TKR from 22% to 44% had minimal effects on
model projections of OA volume. Assuming 22% of the population
with symptomatic end-stage knee OA elects TKR, 21% (2,524,770
individuals) of the subjects alive at 10 years and 27% (2,032,554
individuals) of the subjects alive at 20 years will have symptomatic
advanced or end-stage knee OA. Assuming 44% of the population
with symptomatic end-stage knee OA elects TKR, 20% (2,360,395
individuals) of the subjects alive at 10 years will have symptomatic
advanced or end-stage knee OA.
Discussion
This is the ﬁrst study to project the cumulative incidence of knee
OA in the US population aged 60e64 and estimate the effects of
obesity on incidence and progression of knee OA over 10 years.
Results of our projections revealed that among the 14.3 million US
adults aged 60e64, as deﬁned by 2008 Census population esti-
mates, 10 years from the baseline 11.9 million will still be alive and
2.4 million of these survivors will have symptomatic advanced or
end-stage knee OA.
Our study illustrates and quantiﬁes the relative impact of the
higher risk on knee OA development among obese individuals over
a 10-year time horizon from the population perspective.We limited
our projections to a 10-year time horizon as longer time spans may
have more limited value due to the likely development of new
therapies with structure-modifying properties. These estimates
and other well-established risks of obesity support ongoing public
health efforts to educate non-obese and obese adults about the
importance of weight management. Helping adults achieve and
maintain a healthy BMI will signiﬁcantly reduce the incidence of
new OA cases.
Several prospective population-based studies note a relation-
ship between obesity and rates of OA incidence and/or pro-
gression4,5,23e29. Following the FOS Cohort, investigators
demonstrated that obesity not only precedes onset of knee OA, but
also increases risk for incident OA by an odds ratio of 3.8/2 kg
increase in baseline BMI over 8 years23. In a separate analysis,
investigators showed that a subset of women (in the FOS cohort)
who lost approximately 5 kg over 10 years were half as likely to
develop symptomatic knee OA29. Further, investigators found that
obesity and morbid obesity in the Multicenter Osteoarthritis Study
(MOST) Cohort increased patient risk for incident knee OA by
factors of 2.4 and 3.2 respectively25.
In another projection study, Murphy et al. predicted that the
lifetime risk of developing OA in the Johnston County Osteoarthritis
Project Cohort was 44.7%30. Though we based our projections on
progression estimates from the Johnston County Osteoarthritis
Project in the OAPol Model, our baseline OA prevalence distribu-
tions came from the US population, not the Johnston County Cohort.
In addition, our outcome measure, symptomatic advanced and
end-stage knee OA (KeL 3 or KeL 4 with symptoms), was less
inclusive than the measure used by Murphy et al. (KeL 2þ with
symptoms). These differences make our 10-year projection of
symptomatic advanced or end-stage knee OA difﬁcult to directly
comparewithMurphy et al.’s projection of 44.7%. Both these studies,
however, indicate that obesity augments lifetime risk for kneeOAby
a factor of at least two.
By using a computer simulation model, we project cumulative
rates of symptomatic advanced and end-stage knee OA in a national
sample of US citizens 60e64 years of age, fully accounting for all
sources of mortality and eliminating uncertainty due to loss to
follow-up, pertinent tomanypopulation-based cohorts. Themodestdifference in the estimated proportion of the populationwith OA at
baseline and after 10 years is due primarily to the fact that persons
with OA are more likely to be obese and therefore have lower life
expectancy.
Our projections should be considered within the scope of several
limitations. Our analysis was restricted to a population cohort aged
60e64 years at the baseline, which in 10 years reached 70e74 years
of age. Were a similar simulation for other age groups in the pop-
ulation to be added, increases in the expected number of OA cases
would be greater. Speciﬁcally, if we extended the analyses to subjects
70e74 years old at baseline, mortality would be much higher, and
the proportion of survivors developing OA over a 10-year timeframe
would also be considerably higher. The population-based implica-
tions are highest for the 60e64-year age group.
We made the assumption that the obesity status of adults aged
60e64 does not change over time. While we used published data to
account for small ﬂuctuations in BMI, obesity status, deﬁned by
BMI30 kg/m2 remained stable. A large volume of data suggests that
ﬂuctuations in BMI occurmostly between 25 and 55 years of age, and
by age 60 BMI remains relatively stable31. Therefore, we did not
model changes in BMI in this population. Following subjects in the
NHANES, investigators found that US adults aged 55e64 and 65e74
at the baseline (1971e1975) had on average lost 0.3e0.5 and 1.1e1.7
BMI units (kg/m2) respectively by the 10-year follow-up
(1981e1984)32. We acknowledge that some obese individuals
simulated by the OAPol Model may have been categorized as non-
obese at the 10-year follow-up points had they lost up to 1.7 BMI
units. Finally, recent studies have suggested that the effect of BMI on
rates of knee OA progression is modiﬁed by knee alignment25,33,34.
Because the OAPol Model progression rates were derived from
population-based studies, our obese and non-obese progression
rates are weighted averages for those with varying degrees of
malalignment. The speciﬁcs of the interaction between malalign-
ment and obesity, however, are beyond the scope of this analysis.We
recognize as well that our binary categorization of obesity status
(BMI< 30 vs 30) may obscure associations between obesity, inci-
dence and progression. In fact, the risk for progression to TKR
increased with increasing BMI, even within the non-obese range24.
However, available data on BMI-stratiﬁed OA structural progression
limited us to a somewhat crude (binary) level of granularity.
We used KeL 1 as a proxy for ‘pre-radiographic OA’ acknowl-
edging that the detection of a questionable osteophyte (thedeﬁnition
of KeL 1) may have little bearing on MRI diagnosis of early osteoar-
thritic changes (such as cartilage defects that are not visible on
radiographs). Our rationale is that patients with KeL 1 are known to
be at a greater risk of development of incident early OA (KeL 2),
suggesting that KeL 1 is indeed an early OA state5,35. Our ﬁndings
document the large increase in incidence and prevalence of OA that
would result from using MRI to identify early OA. We suggest that in
the absence of therapeutic interventions that would delay progres-
sion (such as a structure-modifying agent), a large increase in the
number of patients diagnosed with OA would likely lead to more
utilization of imaging, physician visits and other resources, without
obvious structural beneﬁt for the patient. Such increases in health
care utilization will lead to further increases in health care expen-
ditures, without clear evidence of justiﬁcation of such expenses.
Our sensitivity analyses showed that altering progression rates
has a modest impact on the cumulative incidence of symptomatic
advanced and end-stage knee OA. The calibration and validation of
8-year OAPol Model incidence and progression elements demon-
strated that the progression rates used for our main analyses were
comparable to rates found in real US cohorts22,23. In addition, our
calibration of the OAPol Model to data from the FOS provided more
conservative incidence estimates, while our calibration of the
model to original Johnston County Project data provided more
H.L. Holt et al. / Osteoarthritis and Cartilage 19 (2011) 44e50 49liberal estimates. Differences in the rates of knee OA incidence and
progression used in this analysis may be attributed in part to
differences in study sample populations. Subjects in the Johnston
County Project were more racially diverse (81.5% Caucasian and
18.5% African American), had a higher average BMI, were more
likely to live in rural areas, and were younger, on average, than
subjects followed in the FOS Cohort2,23.
In summary, 20% of the surviving cohort or 17% of the baseline
population cohort, totaling 2.4 million adults aged 60e64 at base-
line, will have symptomatic advanced or end-stage OA in 10 years.
Obesity greatly augments patient risk for incident and progressive
knee OA.More sensitive imaging toolsmay lead to higher health care
utilization. Retarding the onset of OA by preventative obesity control
is likely to yield the greatest economic and patient health gains.
Effective and sustainable weight management plans may delay OA
incidence and reduce the risk for a host of associated and costly
chronic conditions including diabetes and heart disease.
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